{
  "source": "PA-Med-Nec-Xphozah.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2331-2\nProgram Prior Authorization/Medical Necessity\nMedication Xphozah® (tenapanor)\nP&T Approval Date 1/2025\nEffective Date 4/1/2025\n1. Background:\nXphozah® (tenapanor) is a sodium hydrogen exchanger 3 (NHE3) inhibitor indicated to reduce\nserum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in\npatients who have an inadequate response to phosphate binders or who are intolerant of any dose\nof phosphate binder therapy.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Xphozah will be approved based upon all of the following criteria:\na. Diagnosis of chronic kidney disease (CKD)\n-AND-\nb. Patient is receiving dialysis\n-AND-\nc. Serum phosphorus is > 6.5 mg/dL\n-AND-\nd. Patient has had an inadequate response to a maximally tolerated dose of two of the\nfollowing phosphate binders:\n(1) calcium acetate (generic PhosLo)\n(2) lanthanum carbonate (generic Fosenrol)\n(3) sevelamer carbonate (generic Renvela)\n(4) Velphoro (sucroferric oxyhydroxide)]\n-AND-\ne. Xphozah will be used as add-on therapy\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n1\nf. Prescribed by or in consultation with a nephrologist.\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Xphozah will be approved based on both the following criterion:\na. Documentation of positive clinical response to Xphozah therapy [e.g., reduction of serum\nphosphorus towards the normal range (3.5 to 5.5 mg/dL)]\n-AND-\nb. Prescribed by or in consultation with a nephrologist.\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (IC",
    "ply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. Reference:\n1. Xphozah® [package insert]. Waltham, MA: Ardelyx, Inc.; October 2023\n2. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and\ndisease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl 3):S1-S201.\n3. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO\nclinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic\nKidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;(113):S1-\nS130. doi:10.1038/ki.2009.188\n4. Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO Chronic\nKidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and\nwhy it matters [published correction appears in Kidney Int. 2017 Dec;92(6):1558]. Kidney Int.\n2017;92(1):26-36. doi:10.1016/j.kint.2017.04.006\nProgram Prior Authorization/Medical Necessity - Xphozah (tenapanor)\nChange Control\n3/2024 New program.\n1/2025 Annual review with no updates.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}